Bright Angel Therapeutics
Leah Cowen is Vice President, Research at the University of Toronto (UofT), Professor in the Department of Molecular Genetics, co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program, and co-Founder and CSO of Bright Angel Therapeutics, a company that leverages state-of-the-art technologies for development of novel antifungal therapeutics. She received her undergraduate degree from the University of British Columbia, a PhD from UofT, and pursued postdoctoral studies at the Whitehead Institute. She has an outstanding track-record of excellence in research, scholarship, and education. She has published >110 high impact research articles and been recognized with many awards including a Burroughs Wellcome Fund Career Award, Grand Challenges Canada Star in Global Health Award, Merck Irving S. Sigal Memorial Award, E.W.R. Steacie Award, and Canada Research Chair in Microbial Genomics & Infectious Disease. She has been elected as Fellow of the American Academy of Microbiology and American Association for the Advancement of Science.
This person is not in any teams
This person is not in any offices
Bright Angel Therapeutics
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance,enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.